Actively Recruiting
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
Led by Fudan University · Updated on 2026-02-10
116
Participants Needed
1
Research Sites
203 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is a randomized, controlled, multicenter, open-label study, planning to enroll 116 subjects with resectable stage II-IIIa squamous NSCLC confirmed by histopathology or cytology, aiming to evaluate the efficacy and safety of serplulimab compared to nivolumab combined with chemotherapy in neoadjuvant therapy. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1036.
CONDITIONS
Official Title
Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 75 years at study entry
- Histopathologically or cytologically confirmed stage II to IIIa squamous non-small cell lung cancer
- Able to tolerate complete lung cancer surgery
- WHO/ECOG performance status of 0 or 1
You will not qualify if you...
- Presence of non-squamous NSCLC types such as adenocarcinoma, mixed squamous-adenocarcinoma, or NSCLC with small cell or neuroendocrine components
- Presence of EGFR sensitivity mutations or ALK, ROS1 gene rearrangements
- Known severe allergy to carboplatin, albumin-bound paclitaxel, or other study drugs
- Central nervous system or leptomeningeal metastases confirmed by imaging or pathology
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here